EGFR  	EGFR  	 NNP	B-NP
mutation  	mutation  	 NN	I-NP
testing  	testing  	 NN	I-NP
in  	in  	 IN	O
non-small  	non-small  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
NSCLC 	NSCLC 	 NNP	B-NP
)  	)  	 -RRB-	O
Lung  	Lung  	 NNP	B-NP
carcinoma  	carcinoma  	 NN	I-NP
is  	is  	 VBZ	O
subdivided  	subdivided  	 VBN	O
into  	into  	 IN	O
small  	small  	 JJ	O
cell  	cell  	 NN	B-NP
carcinoma  	carcinoma  	 NNS	I-NP
and  	and  	 CC	O
non-small  	non-small  	 JJ	B-NP
cell  	cell  	 NN	I-NP
carcinoma  	carcinoma  	 NNS	I-NP
( 	( 	 -LRB-	O
NSCLC 	NSCLC 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
NSCLC  	NSCLC  	 NNP	B-NP
is  	is  	 VBZ	O
heterogeneous  	heterogeneous  	 JJ	B-NP
group  	group  	 NN	I-NP
of  	of  	 IN	I-NP
carcinomas  	carcinomas  	 NN	I-NP
and  	and  	 CC	O
accounts  	accounts  	 NNS	O
for  	for  	 IN	O
70-80 	70-80 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
lung  	lung  	 NN	O
cancer 	cancer 	 NN	O
.  	.  	 .	O
NSCLC  	NSCLC  	 NNP	B-NP
is  	is  	 VBZ	O
further  	further  	 RB	O
divided  	divided  	 VBN	O
into  	into  	 IN	O
adenocarcinoma 	adenocarcinoma 	 NN	B-NP
,  	,  	 ,	O
squamous  	squamous  	 JJ	B-NP
cell  	cell  	 NN	I-NP
carcinoma 	carcinoma 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
large  	large  	 JJ	O
cell  	cell  	 NN	B-NP
carcinoma 	carcinoma 	 NN	I-NP
.  	.  	 .	O
Activating  	Activating  	 JJ	B-NP
somatic  	somatic  	 JJ	I-NP
mutations  	mutations  	 NNS	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
tyrosine  	tyrosine  	 JJ	I-NP
kinase  	kinase  	 JJ	I-NP
domain  	domain  	 NN	I-NP
of  	of  	 IN	I-NP
epidermal  	epidermal  	 JJ	I-NP
growth  	growth  	 NN	I-NP
factor  	factor  	 NN	I-NP
receptor  	receptor  	 NN	I-NP
( 	( 	 -LRB-	O
EGFR 	EGFR 	 NNP	B-NP
)  	)  	 -RRB-	O
have  	have  	 VBP	O
recently  	recently  	 RB	O
been  	been  	 VBN	O
characterized  	characterized  	 VBN	O
in  	in  	 IN	O
a  	a  	 DT	O
subset  	subset  	 NN	B-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
non-small  	non-small  	 JJ	B-NP
cell  	cell  	 NN	I-NP
lung  	lung  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
( 	( 	 -LRB-	O
NSCLC 	NSCLC 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
These  	These  	 DT	O
mutations  	mutations  	 NNS	O
involve  	involve  	 VBP	O
exons  	exons  	 RB	O
18 	18 	 CD	O
,  	,  	 ,	O
19 	19 	 CD	O
,  	,  	 ,	O
20  	20  	 CD	O
and  	and  	 CC	O
21 	21 	 CD	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
harboring  	harboring  	 VBG	O
these  	these  	 DT	O
mutations  	mutations  	 NN	O
in  	in  	 IN	O
their  	their  	 PRP$	O
tumors  	tumors  	 NNS	O
show  	show  	 VBP	O
good  	good  	 JJ	O
response  	response  	 NN	O
to  	to  	 TO	O
EGFR  	EGFR  	 NNP	B-NP
tyrosine  	tyrosine  	 FW	I-NP
kinase  	kinase  	 FW	I-NP
inhibitors  	inhibitors  	 FW	I-NP
( 	( 	 -LRB-	O
EGFR-TKIs 	EGFR-TKIs 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
manuscript  	manuscript  	 NN	O
is  	is  	 VBZ	O
to  	to  	 TO	O
provide  	provide  	 VB	O
an  	an  	 DT	O
overview  	overview  	 NN	B-NP
of  	of  	 IN	I-NP
EGFR  	EGFR  	 NNP	I-NP
mutations  	mutations  	 NNS	I-NP
in  	in  	 IN	O
NSCLC  	NSCLC  	 NNP	B-NP
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 RB	O
to  	to  	 TO	O
briefly  	briefly  	 RB	O
discuss  	discuss  	 VB	O
sample  	sample  	 NN	O
requirements  	requirements  	 NNS	O
and  	and  	 CC	O
testing  	testing  	 NN	B-NP
guidelines  	guidelines  	 NNS	I-NP
for  	for  	 IN	I-NP
EGFR  	EGFR  	 NNP	I-NP
mutation 	mutation 	 NN	I-NP
.  	.  	 .	O
